Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial

March 3, 2025

View Press Release Corporate presentation Contact us
Previous